

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7537998

| | | |
|-----------------------------------|--|-----------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT | |
| NATURE OF CONVEYANCE: | SECURITY INTEREST | |
| CONVEYING PARTY DATA | | |
| | Name | Execution Date |
| | MISSION BIO, INC. | 09/09/2022 |
| RECEIVING PARTY DATA | | |
| Name: | INNOVATUS LIFE SCIENCES LENDING FUND I, LP | |
| Street Address: | 777 THIRD AVENUE | |
| Internal Address: | 25TH FLOOR | |
| City: | NEW YORK | |
| State/Country: | NEW YORK | |
| Postal Code: | 10017 | |
| PROPERTY NUMBERS Total: 30 | | |
| Property Type | Number | |
| Application Number: | 16164595 | |
| Patent Number: | 10501739 | |
| Application Number: | 16658991 | |
| Application Number: | 16839055 | |
| Application Number: | 16310336 | |
| Application Number: | 16639422 | |
| Application Number: | 17423194 | |
| Application Number: | 16749731 | |
| Application Number: | 16839057 | |
| Application Number: | 16839058 | |
| Patent Number: | 11365441 | |
| Application Number: | 17747783 | |
| Application Number: | 16918365 | |
| Application Number: | 16936382 | |
| Application Number: | 16936378 | |
| Application Number: | 17766636 | |
| Application Number: | 17632710 | |
| Application Number: | 17634841 | |
| Application Number: | 17766017 | |

PATENT

| Property Type | Number |
|---------------------|----------|
| Application Number: | 63301706 |
| Application Number: | 63338689 |
| Application Number: | 63317711 |
| Application Number: | 63290158 |
| Application Number: | 63272649 |
| Application Number: | 63292270 |
| Application Number: | 63292272 |
| Application Number: | 63308150 |
| Application Number: | 63327966 |
| Application Number: | 17799495 |
| Application Number: | 63253590 |

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: stokesb@gtlaw.com

Correspondent Name: BETHANY A. STOKES

Address Line 1: GREENBERG TRAURIG, LLP

Address Line 2: ONE INTERNATIONAL PLACE, SUITE 2000

Address Line 4: BOSTON, MASSACHUSETTS 02110

| | |
|--------------------------------|---------------------|
| ATTORNEY DOCKET NUMBER: | 176634.013300 |
| NAME OF SUBMITTER: | BETHANY A. STOKES |
| SIGNATURE: | /Bethany A. Stokes/ |
| DATE SIGNED: | 09/14/2022 |

Total Attachments: 9

source=Innovatus (Mission Bio) - IP Security Agreement (Executed)#page1.tif
source=Innovatus (Mission Bio) - IP Security Agreement (Executed)#page2.tif
source=Innovatus (Mission Bio) - IP Security Agreement (Executed)#page3.tif
source=Innovatus (Mission Bio) - IP Security Agreement (Executed)#page4.tif
source=Innovatus (Mission Bio) - IP Security Agreement (Executed)#page5.tif
source=Innovatus (Mission Bio) - IP Security Agreement (Executed)#page6.tif
source=Innovatus (Mission Bio) - IP Security Agreement (Executed)#page7.tif
source=Innovatus (Mission Bio) - IP Security Agreement (Executed)#page8.tif
source=Innovatus (Mission Bio) - IP Security Agreement (Executed)#page9.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of September 9, 2022 (the “**Effective Date**”) by and between INNOVATUS LIFE SCIENCES LENDING FUND I, LP, a Delaware limited partnership, as collateral agent for the Lenders (the “**Lenders**”) described in the Loan Agreement (as defined below) (in such capacity, the “**Collateral Agent**”), and MISSION BIO, INC., a Delaware corporation (the “**Grantor**”).

RECITALS

A. Lenders have agreed to make certain advances of money and to extend certain financial accommodations to Grantor (the “**Loans**”) in the amounts and manner set forth in that certain Loan and Security Agreement by and among Collateral Agent, the Lenders and Grantor dated as of the date hereof (as the same may be amended, restated, modified or supplemented from time to time, the “**Loan Agreement**”; capitalized terms used herein are used as defined in the Loan Agreement). The Lenders are willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Collateral Agent, for the benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works to secure the obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

To secure its obligations under the Loan Agreement, Grantor grants and pledges to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor’s right, title and interest in, to and under its Intellectual Property Collateral (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto), and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof; provided that in no event shall the Collateral include, and no security interest is granted in, (i) any rights held under a license that are not assignable by their terms without the consent of the licensor thereof (but only to the extent such restriction on assignment is enforceable under applicable law), (ii) any property to the extent that such grant of security interest is prohibited by any applicable law of a Governmental Authority or constitutes a breach or default under or results in the termination of or requires any consent not obtained under, any contract, license, agreement, instrument or other document evidencing or giving rise to such property, except to the extent that such Applicable Law or the term in such contract, license, agreement, instrument or other document providing for such prohibition, breach, default or termination or requiring such consent is ineffective under Section 9-406, 9-407, 9-408 or 9-409 of the Code (or any successor provision or provisions) of any relevant jurisdiction or any other applicable law (including the Bankruptcy Code) or principles of equity; provided, however, that such security interest shall attach immediately at such time as such Applicable Law is not effective or applicable, or such prohibition, breach, default or termination is no longer applicable or is waived, and to the extent severable, shall attach immediately to any portion of the Collateral that does not result in such consequences, or (iii) any intent-to-use trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise.

This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the benefit of the Lenders, under the Loan Agreement. The rights and remedies of Collateral Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Collateral Agent, for the benefit of the Lenders, as a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan

Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Lender, of any or all other rights, powers or remedies.

This Intellectual Property Security Agreement and the rights and obligations of the parties hereunder shall be governed by and construed in accordance with the laws of the State of New York.

[Balance of Page Intentionally Left Blank]


IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

400 E Jamie Court, Suite 100
South San Francisco, CA 94080
Attn: Victoria Tam
Email: victoria.tam@missionbio.com

MISSION BIO, INC.

By: _____
Name: Yan Zhang
Title: Chief Executive Officer and Secretary

COLLATERAL AGENT:

Address of Lender:

777 Third Avenue, 25th Floor
New York, NY 10017
Attn: Claes Ekstrom
Email: cekstrom@innovatusecp.com

INNOVATUS LIFE SCIENCES LENDING FUND
I, LP
By: Innovatus Life Sciences GP, LP
Its: General Partner

By: _____
Name: _____
Title: _____

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

MISSION BIO, INC.

400 E Jamie Court, Suite 100
South San Francisco, CA 94080
Attn: Victoria Tam
Email: victoria.tam@missionbio.com

By: _____
Name: Yan Zhang
Title: Chief Executive Officer and Secretary

COLLATERAL AGENT:

Address of Lender:

INNOVATUS LIFE SCIENCES LENDING FUND
I, LP
By: Innovatus Life Sciences GP, LP
Its: General Partner

777 Third Avenue, 25th Floor
New York, NY 10017
Attn: Claes Ekstrom
Email: cekstrom@innovatuscp.com


By:  _____
Name: Andrew Dym
Title: Authorized Signatory

EXHIBIT A

Copyrights

None.

EXHIBIT B

Patents

| <u>Description</u> | <u>Patent/App. No.</u> | <u>File Date</u> |
|---|------------------------|------------------|
| METHOD, SYSTEMS AND APPARATUS FOR HIGH-THROUGHPUT SINGLE-CELL DNA SEQUENCING WITH DROPLET MICROFLUIDICS | 16/164,595 | 18-Oct-2018 |
| METHOD, SYSTEMS AND APPARATUS FOR SINGLE CELL ANALYSIS | 10,501,739 | 24-Oct-2018 |
| METHOD, SYSTEMS AND APPARATUS FOR SINGLE CELL ANALYSIS | 16/658,991 | 21-Oct-2019 |
| METHODS AND SYSTEMS FOR PROTEOMIC PROFILING AND CHARACTERIZATION | 16/839,055 | 02-Apr-2020 |
| METHODS AND COMPOSITIONS FOR EMULSIFICATION OF SOLID SUPPORTS IN DEFORMABLE BEADS | 16/310,336 | 14-Dec-2018 |
| METHOD AND COMPOSITIONS FOR EVALUATING EMULSION UNIFORMITY | 16/639,422 | 14-Feb-2020 |
| METHOD, APPARATUS AND SYSTEM TO DETECT SUB-PARTICLE FLOWRATE IN A CLOSED SYSTEM | 17/423,194 | 15-Jul-2021 |
| METHODS OF NUCLEIC ACID DETECTION AND PRIMER DESIGN | 16/749,731 | 22-Jan-2020 |
| METHODS, SYSTEMS, AND APPARATUS FOR NUCLEIC ACID DETECTION | 16/839,057 | 02-Apr-2020 |
| METHODS AND SYSTEMS TO CHARACTERIZE TUMORS AND IDENTIFY TUMOR HETEROGENEITY | 16/839,058 | 02-Apr-2020 |
| METHOD AND APPARATUS FOR SIMULTANEOUS TARGETED SEQUENCING OF DNA, RNA AND PROTEIN | 11,365,441 | 22-May-2020 |
| METHOD AND APPARATUS FOR SIMULTANEOUS TARGETED SEQUENCING OF DNA, RNA AND PROTEIN | 17/747,783 | 18-May-2022 |
| METHOD AND APPARATUS TO NORMALIZE QUANTITATIVE READOUTS IN SINGLE-CELL EXPERIMENTS | 16/918,365 | 01-Jul-2020 |
| METHOD, APPARATUS AND SYSTEM TO DETECT INDELS AND TANDEM DUPLICATIONS USING SINGLE CELL DNA SEQUENCING | 16/936,382 | 22-Jul-2020 |
| USING MACHINE LEARNING TO OPTIMIZE ASSAYS FOR SINGLE CELL TARGETED DNA SEQUENCING | 16/936,378 | 22-Jul-2020 |

| <u>Description</u> | <u>Patent/App. No.</u> | <u>File Date</u> |
|---|------------------------|------------------|
| METHODS, SYSTEMS AND APPARATUS FOR COPY NUMBER VARIATIONS AND SINGLE NUCLEOTIDE VARIATIONS SIMULTANEOUSLY DETECTED IN SINGLE-CELLS | 17/766,636 | 05-Apr-2022 |
| METHOD AND APPARATUS FOR SINGLE-CELL ANALYSIS FOR DETERMINING A CELL TRAJECTORY | 17/632,710 | 03-Feb-2022 |
| METHOD, SYSTEM AND APPARATUS FOR MULTI-OMIC SIMULTANEOUS DETECTION OF PROTEIN EXPRESSION, SINGLE NUCLEOTIDE VARIATIONS, AND COPY NUMBER VARIATIONS IN THE SAME SINGLE CELLS | 17/634,841 | 11-Feb-2022 |
| IMPROVED VARIANT CALLER USING SINGLE-CELL ANALYSIS | 17/766,017 | 01-Apr-2022 |
| ENHANCED DETECTION OF TARGET NUCLEIC ACIDS BY REMOVAL OF DNA-RNA CROSS CONTAMINATION | PCT/US2021/018945 | 21-Feb-2021 |
| METHODS AND SYSTEMS INVOLVING DIGESTIBLE PRIMERS FOR IMPROVING SINGLE CELL MULTI-OMIC ANALYSIS | PCT/US2021/017822 | 12-Feb-2021 |
| METHODS AND SYSTEMS INVOLVING DIGESTIBLE PRIMERS FOR IMPROVING SINGLE CELL MULTI-OMIC ANALYSIS | 17/799,495 | 12-Aug-2022 |
| USING MACHINE LEARNING TO OPTIMIZE ASSAYS FOR SINGLE CELL TARGETED SEQUENCING | PCT/US2021/018944 | 21-Feb-2021 |
| SINGLE CELL WORKFLOW FOR WHOLE GENOME AMPLIFICATION | PCT/US2021/023145 | 19-Mar-2021 |
| SINGLE CELL ANALYSIS FOR EPIGENOMIC PROFILING | 63/253,590 | 08-Oct-2021 |
| CELLULAR CLUSTERING ANALYSIS IN SEQUENCING DATASETS | PCT/US2021/060186 | 19-Nov-2021 |
| METHODS OF MOLECULAR TAGGING FOR SINGLE-CELL ANALYSIS | 63/301,706 | 21-Jan-2022 |
| GENE TRANSDUCTION QUANTIFICATION IN SINGLE-CELL SEQUENCING | PCT/US2022/026578 | 27-Apr-2022 |
| ENHANCED DETECTION OF TARGET NUCLEIC ACIDS BY REDUCTION OF OFF-TARGET PROTEASE ACTIVITY | 63/338689 | 05-May-2022 |
| SINGLE CELL INTRACELLULAR PROTEIN ANALYSIS | PCT/US2022/ 026578 | 08-Jun-2022 |
| METHOD, SYSTEM AND APPARATUS FOR FORMING CYCLIC OLEFIN COPOLYMER FLUOROUS | 63/317,711 | 08-Mar-2022 |

| <u>Description</u> | <u>Patent/App. No.</u> | <u>File Date</u> |
|--|------------------------|------------------|
| PRE-ENRICHMENT FOR SINGLE-CELL ANALYSIS FOR DETECTING MEASUREMENTS OF RESIDUAL DISEASE AND ANALYZING CIRCULATING TUMOR CELLS | 63/290,158 | 16-Dec-2021 |
| SINGLE CELL VIRAL INTEGRATION SITE DETECTION USING TRANSPOSONS | 63/272,649 | 27-Oct-2021 |
| SINGLE CELL VIRAL INTEGRATION SITE DETECTION | 63/292,270 | 21-Dec-2021 |
| BARCODED BEADS USEFUL FOR MULTI-OMIC SINGLE-CELL ANALYSIS | 63/292,272 | 21-Dec-2021 |
| DROPLET MERGER DETECTION IN SINGLE CELL SEQUENCING | 63/308,150 | 09-Feb-2022 |
| DE NOVO VARIANT CALLING VIA MULTIANALYTE AND MULTISAMPLE CORRELATION | 63/327,966 | 06-Apr-2022 |

EXHIBIT C

Trademarks

| <u>Description</u> | <u>Serial/Registration No.</u> | <u>File Date</u> |
|--------------------------------------|--------------------------------|------------------|
| Tapestri | 5,599,248 | 06-Nov-2018 |
| Mission Bio | 5,923,816 | 03-Dec-2019 |
| Mission Bio | 87/787,075 | 06-Feb-2018 |
| ONE CELL AT A TIME. | 90/211,441 | 25-Sep-2020 |
| DECODING CANCER. ONE CELL AT A TIME. | 90/211,525 | 25-Sep-2020 |